Ultragenyx - All Time High

Ultragenyx (RARE) is the Barchart Chart of the Day.  The pharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha of 250.50+ and gained 210.86% in the last year.

The Chart of the Day belongs to Ultragenyx (RARE).  I found the pharmaceutical stock by using Barchart to sort today's All Time High list for the stocks with the highest Weighted Alpha then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 5/11 the stock gained 100.07%.

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.

The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 100% Barchart technical buy signals
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 8 new highs and up 32.89% in the last month
• Relative Strength Index 79.48%
• Barchart computes a technical support level at 120.24
• Recently traded at 134.09 with a 50 day moving average of 95.48

Fundamental factors:

• Market Cap $ 4.81 billion
• Analysts didn't release revenue or earnings estimates
• Wall Street analysts issued 6 strong buy and 1 buy recommendation on the stock
• The individual investors posting on Motley Fool expect the stock to beat the market by a vote of 27 to 1

The 50 day moving average vs. price has been an effective technical trading strategy for this stock.